Jan H.M. Schellens

ORCID: 0000-0001-6832-1976

Also affiliated with Utrecht University, The Netherlands Cancer Institute, Oncode Institute, Pharmo Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 9 papers. Top paper: “Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study”.

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Annals of Oncology(2022)10.1016/j.annonc.2021.12.014

N/A

7.1DataRank · unranked

352 citations

Robert J. Kreitman, Zev A. Wainberg, Y. Choi, Jan H.M. Schellens, Jean‐Charles Soria +9 more

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30321-1

N/A

5.7DataRank · unranked

527 citations

Ulrik Lassen, Élena Elez, Antoîne Italiano, Giuseppe Curigliano, Milind Javle +14 more

Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study

Cancer(2020)10.1002/cncr.32883

N/A

4.9DataRank · unranked

150 citations

Emily Bergsland, Bert H. O’Neil, Armando Santoro, Jan H.M. Schellens, Roger B. Cohen +15 more

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature Medicine(2023)10.1038/s41591-023-02321-8

N/A

4.1DataRank · unranked

307 citations

Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein +18 more

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

New England Journal of Medicine(2009)10.1056/nejmoa0900212

N/A

1.2DataRank · unranked

3622 citations

David S. Boss, Timothy A. Yap, Richard Turkington, Peijun Wu, Marja Mergui-Roelvink +14 more

A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide

The Oncologist(2022)10.1093/oncolo/oyac100

N/A

0.790DataRank · unranked

24 citations

Fatima Karzai, Marijo Bilušić, Lisa M. Cordes, Cindy H. Chau, Cody J. Peer +8 more

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis

CPT: Pharmacometrics & Systems Pharmacology(2019)10.1002/psp4.12474

N/A

0.533DataRank · unranked

34 citations

Maarten J. Deenen, Markus Joerger, Hilde Rosing, Niels de Vries, Didier Meulendijks +5 more

Data from Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

(2023)10.1158/1078-0432.c.6520385.v1

N/A

0DataRank · unranked

0 citations

David S. Boss, D. Ross Camidge, Carolyn D. Britten, Jeffrey A. Engelman, Edward B. Garon +9 more

Data from Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

(2023)10.1158/1078-0432.c.6520385

N/A

0DataRank · unranked

0 citations

David S. Boss, D. Ross Camidge, Carolyn D. Britten, Jeffrey A. Engelman, Edward B. Garon +9 more